Search results
Results from the WOW.Com Content Network
Advanced maternal age causes decreased success rates in ovarian hyperstimulation. In ovarian hyperstimulation combined with IUI, women aged 38–39 years appear to have reasonable success during the first two cycles, with an overall live birth rate of 6.1% per cycle. [12] However, for women aged ≥40 years, the overall live birth rate is 2.0% ...
The risk is further increased by multiple doses of hCG after ovulation and if the procedure results in pregnancy. [2] Using a GnRH agonist instead of hCG for inducing final oocyte maturation and/or release results in an elimination of the risk of ovarian hyperstimulation syndrome, but a slight decrease of the delivery rate of approximately 6%. [3]
Controlled ovarian hyperstimulation, which is generally part of in vitro fertilization, and the aim is generally to develop multiple follicles (optimally between 11 and 14 antral follicles measuring 2–8 mm in diameter), [medical citation needed] followed by transvaginal oocyte retrieval, co-incubation, followed by embryo transfer of a maximum ...
Controlled ovarian hyperstimulation is generally part of in vitro fertilization, and the aim is generally to develop multiple follicles (optimally between 11 and 14 antral follicles measuring 2–8 mm in diameter), [5] followed by transvaginal oocyte retrieval, co-incubation, followed by embryo transfer of a maximum of two embryos at a time. [6]
Ovarian hyperstimulation may refer to: Controlled ovarian hyperstimulation; Ovarian hyperstimulation syndrome This page was last edited on 29 ...
Final maturation induction using a GnRH agonist is recommended in women with cancer undergoing fertility preservation, because ovarian hyperstimulation syndrome is associated with an increased risk of arterial thrombotic events such as stroke, myocardial infarction and peripheral arterial embolism, and this risk can add to an already increased ...
Radiation therapy greatly accelerates this decline. Permanent damage occurs with follicular atrophy and reduced follicle numbers. [ 1 ] Consequently these changes lead to uterine dysfunction due to changes in ovarian hormone production which can result in early menopause and risk of infertility.
TVOR is typically performed after ovarian hyperstimulation, where oocytes are pharmacologically stimulated to mature. When the ovarian follicles have reached a certain degree of development, induction of final oocyte maturation is performed, generally by an intramuscular or subcutaneous injection of human chorionic gonadotropin (hCG). [10]